Abstract:The Aurora A kinase (AAK) protein controls spindle assembly and promotes cell divisions in various diseases including cancer. In the present study, allosteric inhibition of AAK protein through different advanced computational screening approaches is employed to target AAK's allosteric inhibition-modulation. Precisely, extensive computational techniques including allosteric binding sites recognition of AAK protein, fingerprint-based similarity search, multi-step molecular docking through AutoDock Vina and PLANTS, and a 100 ns molecular dynamics (MD) simulations studies were carried out followed by the calculation of binding free energy with MM-GBSA based approaches, has been employed for identification of potential allosteric inhibitors-modulators of AAK protein. The study outcome highlighted that all three identified small molecular chemical entities exhibit strong binding interaction affinity in both the docking analyses at the allosteric domain of AAK protein and also greater interaction stability in comparison to the considered standard compound. In addition, all identified three screened hits also show acceptable pharmacokinetics and medicinal chemistry properties, which certainly dictates their potentiality for becoming good drug-like compounds for inhibiting-modulating the activity of AAK protein binds with similar amino acids of the allosteric domain of AAK protein with selected three compounds. All the selected molecules were found to show an acceptable ADMET profile. Moreover, the MM-GBSA-based binding energy was found to be in the range of −8 to −35 Kcal/mol, which showed a strong association between proposed molecules and AAK protein. Comprehensive computational approach shows that the selected proposed three inhibitors of AAK protein are the best candidates as potential inhibitors.

Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases

Discovery and Evaluation of HW161023 As a Potent and Orally Active AAK1 Inhibitor

Development of a novel AAK1 inhibitor via Kinobeads-based screening

Recent Advances in the Development of Casein Kinase 1 Inhibitors

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

AKT kinases as therapeutic targets

In Silico Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal Injury

Recent research and development of DYRK1A inhibitors

A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD)

DYRK1A inhibitors for disease therapy: Current status and perspectives

Deciphering the multifunctional role of dual leucine zipper kinase (DLK) and its therapeutic potential in disease

Molecular and functional characteristics of receptor-interacting protein kinase 1 (RIPK1) and its therapeutic potential in Alzheimer's disease

New targets and designed inhibitors of ASAP Arf-GAPs derived from structural characterization of the ASAP1/440-kD ankyrin-B interaction

Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology

Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.

Therapeutic potential of ASK1 activators in cancer treatment: Current insights and future directions

Identification of Aurora A kinase allosteric inhibitors: A comprehensive virtual screening through fingerprint-based similarity search, molecular docking, machine learning and molecular dynamics simulation

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formation

BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease

Rational design and appraisal of selective Cdc2-Like kinase 1 (Clk1) inhibitors as novel autophagy inducers for the treatment of acute liver injury (ALI)

Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors